Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy
A legfontosabb adatok
- Ki végzi
- Peking Union Medical College Hospital
- Hol
- Beijing (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 2. fázis
- Résztvevők
- 28 fő, tervezett
- Kezdés
- 2026. ápr. 1.
- Várható befejezés
- 2028. okt. 1.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Orelabrutinib
- Romiplostim N01
- A regiszteradat frissítve
- 2026. február 10.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with long-lasting primary immune thrombocytopenia (ITP), a low platelet count caused by the immune system. They must have had at least one earlier ITP treatment.
- Életkor
- 18 to 80 years
- Nem
- All sexes
- A betegség stádiuma
- Chronic primary ITP that has lasted more than 12 months. Daily activity level (ECOG score) 0 to 2. People with severe ITP at screening cannot join.
- Korábbi kezelés
- First-line ITP treatment (corticosteroids and/or intravenous immunoglobulin) did not work well enough, stopped working, or could not be tolerated. Other earlier ITP treatments are allowed, with no limit on the number. People must have responded to an earlier standard ITP treatment once (platelet count ≥50×10⁹/L). During or after the latest treatment, the treatment failed, the disease came back, it could not be tolerated, or the response was lost after stopping.
- Biomarker vagy leletérték
- Earlier platelet count of ≥50×10⁹/L on a past treatment. Failure means platelet count <30×10⁹/L, not doubling from the start, or bleeding.
A részvétel fő kizáró okai
- Bleeding inside the skull within 6 months before screening
- Active infection that cannot be controlled
- A blood clotting disorder other than ITP, or any past cancer
- Past major organ transplant or stem cell/bone marrow transplant
- Known allergy to the study drugs or their ingredients
A regiszter feltételei, szó szerint
Mind a 23 feltétel megnézéseKevesebb
Ki vehet részt
- Subjects voluntarily participate in this study and provide written informed consent;
- Age 18-80 years, inclusive, regardless of gender;
- ECOG score 0 to 2;
- Documented diagnosis of chronic primary Immune Thrombocytopenia (ITP) with a disease duration >12 months;
- Patients with an inadequate sustained response, relapse, intolerance, or insufficient response to first-line ITP therapy (corticosteroids and/or intravenous immunoglobulin). Prior receipt of other ITP treatments is allowed, with no limit on the number of prior lines;
- A history of response to prior standard ITP therapy (defined as achieving a platelet count ≥50×10⁹/L);
- During or following the most recent ITP treatment, patients must have experienced either: treatment failure (platelet count <30×10⁹/L after treatment, or failure to double the baseline count, or occurrence of bleeding), relapse after initial response (platelet count decreased to <30×10⁹/L, or fell below twice the baseline, or bleeding symptoms recurred), treatment intolerance, or an inability to maintain response after treatment discontinuation;
- Subjects demonstrate adequate comprehension of and are able to comply with the study protocol requirements, and are willing to complete the study according to the schedule
Ki nem vehet részt
- Subjects develop intracranial hemorrhage within 6 months prior to screening
- Subjects who, during the treatment period, require rescue therapy based on clinical assessment;
- Subjects have other diseases which mention in protocol
- Active and uncontrollable infection
- Presence of other conditions, as determined by the investigator, that may affect the study results or lead to premature termination of the study;
- Subjects have a history of coagulopathy other than ITP; 7. Subjects with a history of malignancies; 8. History of major organ transplantation or hematopoietic stem cell/bone marrow transplantation; 9. Subjects with a known history of hypersensitivity to the investigational drug as described in the Protocol, or any ingredients; 10. Subjects with a Medication history and surgical history which mention in protocol; 11. Subjects do not meet the criterion of the laboratory test in protocol; Withdrawal Criteria:
- If, after 4 consecutive weeks of Romiplostim N01 administration at the maximum dose (10 µg/kg once weekly), the platelet count remains <50×10⁹/L and the investigator judges the investigational product to be ineffective for the subject, such that continued use is not in the subject's best interest;
- Subjects suffer from severe ITP at screening
- Subjects who are unable to successfully undergo treatment tapering or discontinuation;
- Subjects who withdraw their informed consent
- Occurrence of pregnancy during the trial period
- Poor subject compliance or a significant protocol violation;
- Loss to follow-up;
- The investigator decides that withdrawal is necessary for the subject's safety;
- Study completion or early termination of the entire study
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 80 év között vagy?
Helyszínek itt: Kína
- Peking Union Medical College HospitalBeijing, KínaContact: Tienan Zhu, M.D.Toborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
To evaluate whether orelabrutinib combined with romiplostim N01 can improve the quality of remission, increase the probability of successful drug withdrawal, and prolong the time to treatment failure in patients with primary immune thrombocytopenia (ITP) who have received at least one line of prior therapy.
A vizsgálat csoportja
- Orelabrutinib combined with Romiplostim N01A vizsgált kezelés
The experimental arm will be treated orelabrutinib plus romiplostim N01. The study consists of three phases: 1) Core Treatment Phase (Weeks 1-24): Orelabrutinib 50mg orally once daily (fixed dose) + romiplostim N01 subcutaneously (starting dose 3ug/kg/week, administered once weekly). Platelet count and clinical symptoms are assessed weekly to adjust the dose of romiplostim N01 as appropriate, with a maximum dose of 10ug/kg/week. Patients with platelet count (PLT) \<50×10⁹/L after 28 days of maximum-dose romiplostim N01 withdraw. 2) Tapering Phase (Weeks 25-32): Eligible patients (PLT ≥50×10⁹/L in the last two core phase visits) discontinue orelabrutinib, then taper romiplostim N01 (dose reduction + extended intervals); patients with two consecutive PLT \<30×10⁹/L withdraw. 3) Follow-up Phase (Weeks 33-56): Successfully tapered patients are followed up every 4 weeks to monitor PLT and adverse events (graded per NCI-CTC AE 5.0).
Kezelés: Orelabrutinib és Romiplostim N01
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Phase II Study of Orelabrutinib in Combination With Romiplostim in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received at Least One Prior Line of Therapy
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT07400250: ki vehet részt
- A regiszteradat frissítve
- 2026. február 10.